Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.
Deciphering the Male Breast Cancer Genome
March 5, 2024
Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients.
Oncologist Receives Prestigious MERIT Grant from the National Cancer Institute for Bladder Cancer Research
March 4, 2024
Bishoy M. Faltas, MD, a medical oncologist at NewYork-Presbyterian/Weill Cornell Medicine and Director of Bladder Cancer Research at the Englander Institute for Precision Medicine at Weill Cornell Medicine, was awarded a MERIT grant from the National Cancer Institute at the National Institutes of Health to advance his research into the role of APOBEC3 enzymes in metastatic bladder cancer.
Genetic signature may predict lung cancer response to immunotherapy
February 27, 2024
A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.
The results, published Feb. 23 in Cell Medicine Reports, suggested that this “gene signature” could be used to identify a subclass of lung tumors that is more likely to be eradicated by immunotherapies.
Genetic Signature May Predict Response to Immunotherapy for Non-Small Cell Lung Cancer
February 23, 2024
A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, published in Cell Medicine Reports on Feb.
Less Invasive Early Lung Cancer Study Receives Top 10 Clinical Research Achievement Award
February 22, 2024
A Weill Cornell Medicine-led research team has been awarded a 2024 Top 10 Clinical Research Achievement Award from the Clinical Research Forum in recognition of an influential 2023 New England Journal of Medicine study on early-stage lung cancer resection.
February 2024 EIPM Director's Memo
February 5, 2024
Dear Members of the Englander Institute,
Thank you all for a very productive January!
Who’s Afraid of Early Cancer Detection?
February 4, 2024
A diagnosis of pancreatic cancer usually means a quick death—but not for Roger Royse, who was in Stage II of the disease when he got the bad news in July 2022. The five-year relative survival rate for late-stage metastatic pancreatic cancer is 3%—which means that patients are 3% as likely to live five years after their diagnosis as other cancer-free individuals.
Task force offers guidance to researchers on use of AI
January 22, 2024
A multidisciplinary task force of Cornell faculty and staff has issued a report offering perspectives and practical guidelines for the use of generative artificial intelligence (GenAI) in the practice and dissemination of Cornell’s academic research.
Immunotherapy and Radiation Combo Shows Improved Outcomes for Non-small Cell Lung Cancer
January 11, 2024
A new study reported that patients with non-small cell lung cancer (NSCLC) treated with a combination of low-dose radiation and immunotherapy had higher progression-free survival compared to patients who received immunotherapy alone two years after treatment. The findings from researchers at Weill Cornell Medicine, NewYork-Presbyterian and Columbia University Vagelos College of Physicians and Surgeons offer hope to those affected by NSCLC, the most common type of lung cancer in the United States—81 percent of all lung cancer diagnoses.